Abstract
The prevalence of BRAF V600E in colorectal cancer （CRC） was about 10%. Despite recent therapeutic advances, BRAF V600E mutant CRC is still a challenge with a low response rate and suboptimal survival. Here we reported the safety and preliminary anti-tumor activity of vemurafenib and cetuximab in combination with FOLFIRI for BRAF V600E-mutated advanced CRC patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
